Paper41018484
Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Rojas M and 7 others. Explor Target Antitumor Ther, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer. Papers, record 41018484. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41018484
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References97
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29395328 | CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. | Cell | 2018 | https://conductscience.org/library/papers/29395328 | PubMed |
| 2 | 32047001 | BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32047001 | PubMed |
| 3 | 36307056 | Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2023 | https://conductscience.org/library/papers/36307056 | PubMed |
| 4 | 37069167 | Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. | Nat Commun | 2023 | https://conductscience.org/library/papers/37069167 | PubMed |
| 5 | 34764457 | Fibroblast pyruvate carboxylase is required for collagen production in the tumour microenvironment. | Nat Metab | 2021 | https://conductscience.org/library/papers/34764457 | PubMed |
| 6 | 25119024 | Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. | Nature | 2014 | https://conductscience.org/library/papers/25119024 | PubMed |
| 7 | 39820673 | An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/39820673 | PubMed |
| 8 | 38273133 | Publisher Correction: Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis. | Nature | 2024 | https://conductscience.org/library/papers/38273133 | PubMed |
| 9 | 39475591 | Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/39475591 | PubMed |
| 10 | 33238129 | Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. | Cell Rep | 2020 | https://conductscience.org/library/papers/33238129 | PubMed |
| 11 | 39699311 | Lysosomal-Mitochondrial Interaction Promotes Tumor Growth in Squamous Cell Carcinoma of the Head and Neck. | Mol Cancer Res | 2025 | https://conductscience.org/library/papers/39699311 | PubMed |
| 12 | 29728604 | Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. | Nat Commun | 2018 | https://conductscience.org/library/papers/29728604 | PubMed |
| 13 | 31851936 | Systems-Genetics-Based Inference of a Core Regulatory Network Underlying White Fat Browning. | Cell Rep | 2019 | https://conductscience.org/library/papers/31851936 | PubMed |
| 14 | 38052910 | Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. | Nat Med | 2024 | https://conductscience.org/library/papers/38052910 | PubMed |
| 15 | 29949778 | Targeting a Sirt5-Positive Subpopulation Overcomes Multidrug Resistance in Wild-Type Kras Colorectal Carcinomas. | Cell Rep | 2018 | https://conductscience.org/library/papers/29949778 | PubMed |
| 16 | 26457759 | The consensus molecular subtypes of colorectal cancer. | Nat Med | 2015 | https://conductscience.org/library/papers/26457759 | PubMed |
| 17 | 29891662 | Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/29891662 | PubMed |
| 18 | 31439581 | A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31439581 | PubMed |
| 19 | 38216672 | TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma. | Oncogene | 2024 | https://conductscience.org/library/papers/38216672 | PubMed |
| 20 | 31825825 | CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies. | Cell Rep | 2019 | https://conductscience.org/library/papers/31825825 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941901 | Metabolic Dysfunction and T-Cell Exhaustion in Colorectal Cancer: Mechanisms, Microenvironment Remodeling, and Therapeutic Opportunities. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941901 | PubMed |
| 42910173 | Identification of Immuno-Diagnostic and Therapeutic Markers in Tumors and Inflammatory Diseases Based on Single-Cell and Machine Learning Methods. | Hum Mutat | 2026 | https://conductscience.org/library/papers/42910173 | PubMed |
| 42528626 | Convergent adaptive architectures linking chemoresistance and radioresistance in chemoradiotherapy: a systems-level perspective. | Front Oncol | 2026 | https://conductscience.org/library/papers/42528626 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41018484
GET https://conductscience.org/api/papers/v1/41018484/references?page=2